Chemoprevention of mammary carcinogenesis by sustained systemic delivery of ellagic acid

European Journal of Cancer Prevention

Volumn 20, Issue 6, 2011, Pages 484-491

  Vadhanam, Manicka V ^a   Ravoori, Srivani ^a   Aqil, Farrukh ^a   Gupta, Ramesh C ^a,b  

^a UNIVERSITY OF LOUISVILLE   (United States)

^b University of Louisville School of Medicine   (United States)

Author keywords

breast cancer; chemoprevention; drug delivery; ellagic acid; natural products

Indexed keywords

ELLAGIC ACID; ESTROGEN; PROLACTIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER CONTROL; CANCER INCIDENCE; CHEMOPROPHYLAXIS; CONTROLLED STUDY; DIET; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG DOSE REDUCTION; DRUG EFFICACY; FEMALE; NONHUMAN; PRIORITY JOURNAL; RAT; SYSTEMIC THERAPY; TREATMENT DURATION; TUMOR VOLUME;

ANIMALS; DRUG DELIVERY SYSTEMS; DRUG IMPLANTS; ELLAGIC ACID; FEMALE; MAMMARY NEOPLASMS, EXPERIMENTAL; PROLACTIN; RANDOM ALLOCATION; RATS; RATS, INBRED ACI;

EID: 80053641408     PISSN: 09598278     EISSN: 14735709     Source Type: Journal    
DOI: 10.1097/CEJ.0b013e3283498e00     Document Type: Article

References (43)

1. ACS (2009). Cancer Facts & Figures 2009. In: American Cancer Society. Atlanta: American Cancer Society. http://www.cancer.org/Research/Cancer FactsFigures/CancerFactsFigures/cancer-facts-figures-2009.
2. Ahn D, Putt D, Kresty L, Stoner GD, Fromm D, Hollenberg PF (1996). The effects of dietary ellagic acid on rat hepatic and esophageal mucosal cytochromes P450 and phase II enzymes. Carcinogenesis 17:821-828. (Pubitemid 26129699)
3. Aiyer HS, Gupta RC (2010). Berries and ellagic acid prevent estrogen-induced mammary tumorigenesis by modulating enzymes of estrogen metabolism. Cancer Prev Res (Phila Pa) 3:727-737.
4. Aiyer HS, Kichambare S, Gupta RC (2008). Prevention of oxidative DNA damage by bioactive berry components. Nutr Cancer 60 (Suppl 1): 36-42.
5. Aiyer HS, Vadhanam MV, Stoyanova R, Caprio GD, Clapper ML, Gupta RC (2008). Dietary berries and ellagic acid prevent oxidative DNA damage and modulate expression of DNA repair genes. Int J Mol Sci 9:327-341. (Pubitemid 351482118)
6. Bansal SS, Vadhanam MV, Gupta RC (2011). Development and in vitro-in vivo evaluation of polymeric implants for continuous systemic delivery of curcumin. Pharm Res 28:1121-1130.
7. Barch DH, Rundhaugen LM (1994). Ellagic acid induces NAD(P)H:quinone reductase through activation of the antioxidant responsive element of the rat NAD(P)H:quinone reductase gene. Carcinogenesis 15:2065-2068. (Pubitemid 24303063)
8. Barch DH, Rundhaugen LM, Thomas PE, Kardos P, Pillay NS (1994). Dietary ellagic acid inhibits the enzymatic activity of CYP1A1 without altering hepatic concentrations of CYP1A1 or CYP1A1 mRNA. Biochem Biophys Res Commun 201:1477-1482. (Pubitemid 24234255)
9. Boukharta M, Jalbert G, Castonguay A (1992). Biodistribution of ellagic acid and dose-related inhibition of lung tumorigenesis in A/J mice. Nutr Cancer 18:181-189.
10. Cribb AE, Knight MJ, Dryer D, Guernsey J, Hender K, Tesch M, et al. (2006). Role of polymorphic human cytochrome P450 enzymes in estrone oxidation. Cancer Epidemiol Biomarkers Prev 15:551-558.
11. Cuzick J, Powles T, Veronesi U, Forbes J, Edwards R, Ashley S, et al. (2003). Overview of the main outcomes in breast-cancer prevention trials. Lancet 361:296-300. (Pubitemid 36126189)
12. Daniel EM, Stoner GD (1991). The effects of ellagic acid and 13-cis-retinoic acid on N-nitrosobenzylmethylamine-induced esophageal tumorigenesis in rats. Cancer Lett 56:117-124.
13. Das M, Bickers DR, Mukhtar H (1985). Effect of ellagic acid on hepatic and pulmonary xenobiotic metabolism in mice: studies on the mechanism of its anticarcinogenic action. Carcinogenesis 6:1409-1413. (Pubitemid 16238932)
14. Dixit R, Teel RW, Daniel FB, Stoner GD (1985). Inhibition of benzo(a)pyrene and benzo(a)pyrene-trans-7,8-diol metabolism and DNA binding in mouse lung explants by ellagic acid. Cancer Res 45:2951-2956. (Pubitemid 15007155)
15. Fabian CJ, Kimler BF, Brady DA, Mayo MS, Chang CH, Ferraro JA, et al. (2002). A phase II breast cancer chemoprevention trial of oral alpha-difluoromethy-lornithine: breast tissue, imaging, and serum and urine biomarkers. Clin Cancer Res 8:3105-3117. (Pubitemid 35155020)
16. Fabian CJ, Kimler BF, Anderson J, Tawfik OW, Mayo MS, Burak WE Jr., et al. (2004). Breast cancer chemoprevention phase I evaluation of biomarker modulation by arzoxifene, a third generation selective estrogen receptor modulator. Clin Cancer Res 10:5403-5417. (Pubitemid 39100477)
17. Hu M (2007). Commentary: bioavailability of flavonoids and polyphenols: call to arms. Mol Pharm 4:803-806.
18. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ (2009). Cancer statistics. CA Cancer J Clin 59:225-249.
19. Kelloff GJ, Lippman SM, Dannenberg AJ, Sigman CC, Pearce HL, Reid BJ, et al. (2006). Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer-a plan to move forward. Clin Cancer Res 12:3661-3697. (Pubitemid 44000248)
20. Liehr JG (2000). Is estradiol a genotoxic mutagenic carcinogen? Endocr Rev 21:40-54. (Pubitemid 32260395)
21. Mandal S, Stoner GD (1990). Inhibition of N-nitrosobenzylmethylamine- induced esophageal tumorigenesis in rats by ellagic acid. Carcinogenesis 11:55-61. (Pubitemid 20050736)
22. Narayanan BA, Geoffroy O, Willingham MC, Re GG, Nixon DW (1999). p53/p21(WAF1/CIP1) expression and its possible role in G1 arrest and apoptosis in ellagic acid treated cancer cells. Cancer Lett 136:215-221. (Pubitemid 29167185)
23. Nelson HD, Fu R, Griffin JC, Nygren P, Smith MEB, Humphrey L (2009). Systematic review: comparative effectiveness of medications to reduce risk for primary breast cancer. Annals of Internal Medicine 151:703-715.
24. Paluszczak J, Krajka-Kuzniak V, Baer-Dubowska W (2010). The effect of dietary polyphenols on the epigenetic regulation of gene expression in MCF7 breast cancer cells. Toxicol Lett 192:119-125.
25. Papoutsi Z, Kassi E, Tsiapara A, Fokialakis N, Chrousos GP, Moutsatsou P (2005). Evaluation of estrogenic/antiestrogenic activity of ellagic acid via the estrogen receptor subtypes ERalpha and ERbeta. J Agric Food Chem 53:7715-7720. (Pubitemid 41499614)
26. Power J, French R, Cowan F (2007). Subdermal implantable contraceptives versus other forms of reversible contraceptives or other implants as effective methods of preventing pregnancy. Cochrane Database Syst Rev 3:1-36. 10.1002/14651858.CD001326.pub2. (Pubitemid 351805660)
27. Ravoori S, Vadhanam MV, Sahoo S, Srinivasan C, Gupta RC (2007). Mammary tumor induction in ACI rats exposed to low levels of 17beta-estradiol. Int J Oncol 31:113-120.
28. Revel A, Raanani H, Younglai E, Xu J, Rogers I, Han R, et al. (2003). Resveratrol, a natural aryl hydrocarbon receptor antagonist, protects lung from DNA damage and apoptosis caused by benzo[a]pyrene. J Appl Toxicol 23:255-261. (Pubitemid 36950295)
29. Sasano H, Suzuki T, Nakata T, Moriya T (2006). New development in intracrinology of breast carcinoma. Breast Cancer 13:129-136.
30. Shull JD, Spady TJ, Snyder MC, Johansson SL, Pennington KL (1997). Ovary-intact, but not ovariectomized female ACI rats treated with 17beta-estradiol rapidly develop mammary carcinoma. Carcinogenesis 18:1595-1601. (Pubitemid 28134784)
31. Simpson ER (2003). Sources of estrogen and their importance. J Steroid Biochem Mol Biol 86:225-230. (Pubitemid 37412561)
32. Singletary K, Liao CH (1989). Ellagic acid effects on the carcinogenicity, DNA-binding and metabolism of 7,12-dimethylbenz(a)anthracene (DMBA). In Vivo 3:173-175.
33. Smart RC, Huang MT, Chang RL, Sayer JM, Jerina DM, Conney AH (1986). Disposition of the naturally occurring antimutagenic plant phenol, ellagic acid, and its synthetic derivatives, 3-O-decylellagic acid and 3,3'-di-O-methylel- lagic acid, in mice. Carcinogenesis 7:1663-1667.
34. Smith WA, Gupta RC (1996). Use of a microsome-mediated test system to assess efficacy and mechanisms of cancer chemopreventive agents. Carcinogenesis 17:1285-1290. (Pubitemid 26196341)
35. Smith WA, Arif JM, Gupta RC (1998). Effect of cancer chemopreventive agents on microsome-mediated DNA adduction of the breast carcinogen diben-zo[a,l]pyrene. Mutat Res 412:307-314. (Pubitemid 28218261)
36. Srinivasan P, Vadhanam MV, Arif JM, Gupta RC (2002). A rapid screening assay for antioxidant potential of natural and synthetic agents in vitro. Int J Oncol 20:983-986.
37. Stoner GD, Mukhtar H (1995). Polyphenols as cancer chemopreventive agents. J Cell Biochem Suppl 22:169-180.
38. Stoner GD, Sardo C, Apseloff G, Mullet D, Wargo W, Pound V, et al. (2005). Pharmacokinetics of anthocyanins and ellagic acid in healthy volunteers fed freeze-dried black raspberries daily for 7 days. J Clin Pharmacol 45:1153-1164. (Pubitemid 41361915)
39. Stoner GD, Wang LS, Casto BC (2008). Laboratory and clinical studies of cancer chemoprevention by antioxidants in berries. Carcinogenesis 29:1665-1674.
40. Tasaki M, Umemura T, Maeda M, Ishii Y, Okamura T, Inoue T, et al. (2008). Safety assessment of ellagic acid, a food additive, in a subchronic toxicity study using F344 rats. Food Chem Toxicol 46:1119-1124.
41. Teel RW, Martin RM (1988). Disposition of the plant phenol ellagic acid in the mouse following oral administration by gavage. Xenobiotica 18:397-405.
42. Whitley AC, Stoner GD, Darby MV, Walle T (2003). Intestinal epithelial cell accumulation of the cancer preventive polyphenol ellagic acid-extensive binding to protein and DNA. Biochem Pharmacol 66:907-915. (Pubitemid 37083587)
43. Wiklund J, Wertz N, Gorski J (1981). A comparison of estrogen effects on uterine and pituitary growth and prolactin synthesis in F344 and Holtzman rats. Endocrinology 109:1700-1707. (Pubitemid 12197465)